Society of Hematologic Oncology Annual Meeting (SOHO)

Brad S. Kahl, MD, discusses how BTK inhibitors and MRD-guided treatment may help patients with frontline mantle cell lymphoma avoid transplantation.

Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD, explains how safety, resistance, and sequencing guide frontline therapy selection in CLL.

Brad S. Kahl, MD, discusses how the TRIANGLE trial supports frontline therapy without autologous transplantation in mantle cell lymphoma.

Elise A. Chong, MD, discusses real-world liso-cel efficacy and safety, outpatient use, and future directions in relapsed/refractory mantle cell lymphoma.

Brad S. Kahl, MD, discusses TRIANGLE and EA4151 data reshaping ASCT use in frontline MCL, induction intensity, and high-risk disease strategies.

Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD, discusses recent CLL approvals, BTK and BCL-2 inhibitor safety, and individualizing frontline therapy.

Prithviraj Bose, MD, discusses spleen response and early survival data from the phase 3 SENTRY trial in JAK inhibitor-naive myelofibrosis.

Tapan M. Kadia, MD, details the dosing, tolerability, and response data with the use of dibotatug in patients with large granular lymphocytic leukemia.

The ASC4FIRST trial continued to show higher molecular response rates and better tolerability with asciminib than with standard TKIs in Ph-positive CML.

Rusfertide preserved efficacy and safety benefits over placebo in both low- and high-risk polycythemia vera.

Prithviraj Bose, MD, discusses selinexor's existing myeloma approval and how phase 3 SENTRY data could shape its use with ruxolitinib in myelofibrosis.

Naseema Gangat, MBBS, reviews cohort-specific hematologic response rates and safety findings for selcodebart in myelofibrosis.

In the PIVOT-CLL trial, time-limited pirtobrutinib, venetoclax, and obinutuzumab produced deep, durable molecular remissions in treatment-naive CLL.

A prespecified analysis showed benefit with anselamimab in patients with kappa light chain AL amyloidosis.

David Sallman, MD, discusses planned development and combination strategies for the NEK7 inhibitor ofirnoflast in lower-risk MDS.

Actinomycin D plus low-dose cytarabine and venetoclax produced high remission rates in a retrospective cohort of patients with NPM1-mutated AML.

Revumenib added to intensive chemotherapy produced deep, MRD-negative remissions with a manageable safety profile in newly diagnosed AML.

Naseema Gangat, MBBS, discusses phase 2 efficacy and safety data for DISC-3405, an anti-TMPRSS6 monoclonal antibody, in polycythemia vera.

Ofirnoflast produced hematologic improvement in two-thirds of patients with ESA-refractory lower-risk MDS.

In the phase 2 RESTORE-PV trial, DISC-3405 cut phlebotomy events and maintained hematocrit below 45% in patients with polycythemia vera.

Selcodebart improved hemoglobin levels and transfusion independence across 3 anemia cohorts in myelofibrosis, regardless of concomitant JAK inhibitor use.

Hematology experts highlight the MDS, lymphoma, and myeloma data they were most excited to see at the 2025 SOHO Annual Meeting.

A chemotherapy-free regimen of mosunetuzumab and polatuzumab vedotin improved PFS and response rates vs R-GemOx in relapsed/refractory LBCL.

Treatment with mosunetuzumab plus polatuzumab vedotin yielded high response rates and had a manageable safety profile in BTK inhibitor–exposed MCL.

Loncastuximab tesirine plus glofitamab demonstrated early promise in patients with relapsed or refractory large B-cell lymphoma.

Ghayas C. Issa, MD, MS, discusses the optimal timing of and approaches to genetic testing for NPM1 and KMT2A alterations in AML.

Frontline treatment with mosunetuzumab showed high antitumor activity in patients with marginal zone lymphoma regardless of risk status.

Treatment with an investigational allogeneic T-cell immunotherapy improved outcomes vs conventional transplant in patients with hematologic malignancies